Welcome to our dedicated page for AgomAb Therapeutics NV news (Ticker: AGMB), a resource for investors and traders seeking the latest updates and insights on AgomAb Therapeutics NV stock.
Agomab Therapeutics NV reports news centered on its clinical-stage fibro-inflammatory disease pipeline, public-company financing, and intellectual-property position. Company updates have covered ontunisertib in fibrostenosing Crohn's disease, AGMB-447 in idiopathic pulmonary fibrosis, U.S. patent protection for AGMB-447, and regulatory interactions related to clinical-study design.
Recurring AGMB news also includes financial results, cash runway commentary, Nasdaq ADS trading status, initial public offering activity, and annual meeting or governance materials for the Belgian foreign private issuer.
Agomab Therapeutics (AGMB) reports that shareholders approved all resolutions at its Special and Extraordinary General Shareholders' Meeting held on September 11, 2026.
Approvals include the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors and the consolidation and split adjustment of outstanding pre-IPO warrants. The warrant changes align these instruments with the share split implemented in connection with Agomab's IPO in February 2026. Meeting materials, including biographies of the new Board members, are available on the company’s website.
Agomab Therapeutics (AGMB) will participate in several investor conferences in New York in September 2026, featuring fireside chats at multiple events.
The company plans to attend Citi's 2026 Biopharma Back to School Conference on September 10, the 2026 Cantor Global Healthcare Conference on September 11, the H.C. Wainwright 28th Annual Global Investment Conference on September 15, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16.
Agomab Therapeutics (Nasdaq: AGMB) announced that its Board has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive directors, subject to shareholder approval at a Special General Meeting on September 11, 2026 in Antwerp, Belgium. Garcia is President, CEO and director of Dianthus Therapeutics (Nasdaq: DNTH), while Dr. Patel is Chief Medical Officer of CRISPR Therapeutics (Nasdaq: CRSP).
Agomab will also hold an Extraordinary General Shareholders’ Meeting the same day at 2:30 PM CEST to seek approval for a proposed consolidation and split of outstanding pre-IPO warrants, adjusting each warrant to reflect the share split implemented with Agomab’s February 2026 IPO. Meeting materials and detailed biographies are available on Agomab’s investor website.
Agomab (Nasdaq: AGMB) reported unaudited half year 2026 results and confirmed its 2026 outlook, highlighting clinical, regulatory and financing progress. Cash, cash equivalents and short-term investments totaled €252.0 million at June 30, 2026, supported by approximately $208 million in gross IPO proceeds, which Agomab expects will fund operations into the first half of 2029.
According to the company, regulatory alignment with the FDA has been achieved on key elements of the NOV-ERA Phase 2b ontunisertib study in fibrostenosing Crohn’s disease, with first dosing planned in the second half of 2026. A Phase 2 study of AGMB-447 in idiopathic pulmonary fibrosis is also targeted to start in the second half of 2026, with multiple topline datasets from ongoing studies expected in the coming months. For the six months ended June 30, 2026, Agomab reported R&D expenses of €23.0 million, G&A expenses of €12.2 million, and a net loss of €31.0 million, compared to €26.9 million a year earlier.
Agomab (Nasdaq: AGMB) outlined the NOV-ERA Phase 2b trial design evaluating oral ALK5 inhibitor ontunisertib in fibrostenosing Crohn’s disease (FSCD).
The randomized, double-blind, placebo-controlled study will enroll up to 320 adults globally, use endoscopic passability at Week 24 as the primary endpoint, and plans first dosing in 2H 2026 following regulatory and ethics approvals.
Agomab (Nasdaq: AGMB)/b) reported results of its Annual General Meeting held May 26, 2026. Shareholders approved all agenda items, including the statutory financial statements for the year ended December 31, 2025, discharge of directors and auditor, and the reappointments of and Tim Knotnerus.
AGM documents and detailed voting results are available on Agomab’s investor relations website.
Agomab Therapeutics (Nasdaq: AGMB) announced participation in several 2026 scientific and investor conferences. Events include a poster on AGMB-447 for idiopathic pulmonary fibrosis at the ATS International Conference and multiple fireside chats and investor meetings across New York, London, San Diego, and Boston.
Agomab (NASDAQ: AGMB)/b) reported full-year 2025 results and confirmed 2026 outlook. Key financials: at 31-Dec-2025, and $208M gross IPO proceeds in Feb-2026, expected to fund operations into the first half of 2029.
Clinical: positive STENOVA Phase 2a topline with ontunisertib, FDA/MHRA alignment on Phase 2 designs, USPTO patent for AGMB-447, and planned initiation of two Phase 2 studies in H2 2026; topline OLE and IPF cohort data expected H2 2026.
Agomab (Nasdaq: AGMB) announced the USPTO granted U.S. Patent No. 12,577,230 for AGMB-447, its investigational inhaled, lung-restricted small molecule ALK5 inhibitor. The patent covers composition of matter in the U.S. through at least 2041, excluding potential extensions.
AGMB-447 is in a Phase 1b study for idiopathic pulmonary fibrosis (IPF); healthy-subject data were described as positive and patient-cohort results are expected later in 2026. AGMB-447 is not approved and its safety and efficacy remain unestablished.
Agomab (Nasdaq: AGMB) closed its initial public offering of 12,500,000 ADSs at $16.00 per ADS, generating approximately $200.0 million in gross proceeds before underwriting discounts, commissions and offering expenses. The ADSs began trading on the Nasdaq Global Select Market on February 6, 2026.
Joint book-running managers included J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen; the registration statement was declared effective January 30, 2026.